Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Janux Therapeutics has raised $350.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
Janux Therapeutics's investors include RA Capital Management, Janus Henderson Investors, Samsara BioCapital, OrbiMed, Correlation Ventures.
Janux Therapeutics is headquartered in La Jolla, United States.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Janux Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Janux Therapeutics — Funding & Investors." VCBacked, December 3, 2024, https://www.vcbacked.co/company/janux-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Janux Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/janux-therapeutics
{{cite web |title=Janux Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/janux-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated